Catalyst Pharmaceuticals Partners, Inc.
As filed with the Securities and Exchange Commission on
October 18, 2006
Registration No. 333-136039
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Amendment No. 4
to
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
CATALYST PHARMACEUTICAL PARTNERS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
2834 |
|
76-0837053 |
(State or other jurisdiction of
incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification Number) |
220 Miracle Mile
Suite 234
Coral Gables, Florida 33134
(305) 529-2522
(Name, address, including zip code, and telephone number,
including area code, of registrants principal executive
offices)
Patrick J. McEnany
Chief Executive Officer
Catalyst Pharmaceutical Partners, Inc.
220 Miracle Mile
Suite 234
Coral Gables, Florida 33134
(305) 529-2522
(Name, address, including zip code, and telephone number,
including area code,
of agent for service)
Copies To:
|
|
|
Philip B. Schwartz, Esq.
Akerman Senterfitt
One Southeast Third Avenue
Miami, Florida 33131
(305) 374-5600 |
|
Donald J. Murray, Esq.
Dewey Ballantine LLP
1301 Avenue of the Americas
New York, New York 10019-6092
(212) 259-8000 |
Approximate date of commencement of proposed sale to
public: As soon as practicable after this registration
becomes effective
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act, check the following
box: o
If this Form is used to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act,
check the following box and list the Securities Act registration
number of the earlier effective registration statement for the
same
offering: o
If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering: o
If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following
box and list the Securities Act registration number of the
earlier effective registration statement for the same
offering: o
The registrant hereby amends this registration statement on
such date or dates as may be necessary to delay its effective
date until the registrant shall file a further amendment which
specifically states that this registration statement shall
become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until the registration statement shall
become effective on such date as the Commission, acting pursuant
to Section 8(a), may determine.
EXPLANATORY NOTE
This Amendment No. 4 to the Form S-1 is being filed solely to
file Exhibit 5.1.
PART II
Information Not Required In Prospectus
Item 13. Other Expenses of
Issuance and Distribution
The following table sets forth the various costs and expenses to
be incurred in connection with the issuance and distribution of
the securities registered under this Registration Statement,
other than underwriting discounts and commissions. All such
expenses are estimates, except for the SEC registration fee, the
NASD filing fee, and the Nasdaq Global Market listing fee. The
following expenses will be borne solely by the Registrant.
|
|
|
|
|
SEC Registration Fee
|
|
$ |
4,306.75 |
|
NASD Filing Fee
|
|
|
4,525.00 |
|
Nasdaq Global Market Listing Fee
|
|
|
100,000.00 |
|
Printing and Engraving Expenses
|
|
|
200,000.00 |
|
Legal Fees and Expenses
|
|
|
450,000.00 |
|
Accounting Fees and Expenses
|
|
|
100,000.00 |
|
Transfer Agent and Registrar Fees
|
|
|
20,000.00 |
|
Miscellaneous Expenses
|
|
|
121,168.25 |
|
|
|
|
|
Total
|
|
$ |
1,000,000.00 |
|
|
|
|
|
Item 14. Indemnification of
Officers and Directors
Section 145 of the Delaware General Corporation Law
permits, in general, a Delaware corporation to indemnify any
person who was or is a party to any proceeding (other than an
action by, or in the right of, the corporation) by reason of the
fact that he or she is or was a director or officer of the
corporation, or served another business enterprise in any
capacity at the request of the corporation, against liability
incurred in connection with such proceeding, including the
estimated expenses of litigating the proceeding to conclusion
and the expenses actually and reasonably incurred in connection
with the defense or settlement of such proceeding, if such
person acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, the best interests of the
corporation and, in criminal actions or proceedings,
additionally had no reasonable cause to believe that his or her
conduct was unlawful. A Delaware corporations power to
indemnify applies to actions brought by or in the right of the
corporation as well, but only to the extent of expenses
(including attorneys fees) actually and reasonably
incurred by the person in connection with the defense or
settlement of the action or suit, provided that no
indemnification shall be provided in such actions in the event
of any adjudication of negligence or misconduct in the
performance of such persons duties to the corporation,
unless a court believes that in light of all the circumstances
indemnification should apply. Section 145 of the Delaware
General Corporation Law also permits, in general, a Delaware
corporation to purchase and maintain insurance on behalf of any
person who is or was a director or officer of the corporation,
or served another entity in any capacity at the request of the
corporation, against liability incurred by such person in such
capacity, whether or not the corporation would have the power to
indemnify such person against such liability.
The Registrants By-Laws implement the indemnification
provisions permitted by Section 145 of the Delaware General
Corporation Law by providing that:
|
|
|
|
|
The Registrant shall indemnify any person that was or is a party
to any proceeding by reason of the fact that he or she is or was
a director or an officer of the Registrant, to the fullest
extent permitted by the Delaware General Corporation Law. |
|
|
|
The Registrant shall prepay expenses, including attorneys
fees, incurred by a director or an officer in connection with
defending a proceeding for which the Registrant is required to
provide indemnification, |
II-1
|
|
|
|
|
provided that the director or the officer shall undertake to
repay such advances if it is ultimately determined that such
person is not entitled to indemnification for such expenses. |
|
|
|
The Registrant shall pay a claim for indemnification or
advancement of expenses within 30 days after it receives a
written claim from an indemnified director or officer. Such
director or officer may file suit to recover the unpaid claim
amount, and the corporation shall have the burden of proving
that the director or officer is not entitled to the requested
claim amount. |
|
|
|
The grant of indemnification rights by the registrant shall not
be exclusive of any other rights that an indemnified director or
officer may have or hereafter acquire under any statute,
agreement, vote of stockholders or disinterested directors, or
provision of the Certificate of Incorporation or the by-laws of
the Registrant. |
|
|
|
The Registrants obligation, if any, to indemnify or to
advance expenses to any indemnified person who was or is serving
another corporation, partnership, joint venture, trust,
enterprise or non-profit enterprise shall be reduced by any
amount such employee may collect as indemnification or
advancement of expenses from the other corporation, partnership,
joint venture, trust, enterprise or non-profit enterprise. |
|
|
|
The Registrant may, in its discretion, indemnify and advance
expenses to employees and agents, to the extent and manner
permitted by law, under circumstances where indemnification is
not required by law. |
In addition, as permitted by Section 102 of the Delaware
General Corporation Law, the Registrants Certificate of
Incorporation includes a provision that eliminates the personal
liability of its directors for monetary damages for breach of
their fiduciary duty as directors to the fullest extent
permitted by the Delaware General Corporation Law.
These indemnification provisions may be sufficiently broad to
permit indemnification of the Registrants directors and
officers for liabilities (including reimbursement of expenses
incurred) arising under the Securities Act. Pursuant to the
Underwriting Agreement to be filed as Exhibit 1.1 to this
Registration Statement, the underwriters have agreed to
indemnify the Registrants directors, officers, and
controlling persons, and the Registrant has agreed to indemnify
the underwriters, against certain civil liabilities that may be
incurred in connection with the offering of securities pursuant
to this Registration Statement (including certain liabilities
under the Securities Act) as a result of any statement or
omission in this Registration Statement, in the related
prospectus, in any preliminary prospectus, or in any amendment
or supplement thereto, in each case to the extent that the
statement or omission was made in reliance upon and in
conformity with written information furnished by the
underwriters expressly for use therein.
Item 15. Recent Sales of
Unregistered Securities
The following is information furnished with regard to all
securities sold by the Registrant within the past three years
that were not registered under the Act.
On February 28, 2005, the Registrant completed a rights
offering of shares of its authorized but unissued common stock
to holders of its common stock and holders of its Series A
Preferred Stock. In the rights offering, the Registrant issued
3,954,483 shares of its common stock to its stockholders. No
commissions were paid in connection with the issuance of the
foregoing shares, all of which were issued pursuant to an
exemption from registration under Section 4(2) of the Act.
This offering resulted in proceeds of approximately $1,000,000
to the Registrant, net of expenses.
On July 24, 2006, the Registrant completed the sale of
7,644 shares of its Series B Preferred Stock, par value
$0.01 per share at a price of $435 per share. The foregoing
securities were issued to 51 accredited investors and were
issued pursuant to an exemption from registration under
Section 4(2) of the Act.
II-2
In July 2006, the Registrant issued an aggregate of 142,274
shares of its common stock to five of its advisors for services
performed during 2005 and through June 30, 2006. These
shares were issued pursuant to an exemption from registration
under Section 4(2) of the Act.
None of these transactions involved any underwriters,
underwriting discounts, or any public offering. The recipients
of securities in each transaction represented their intention to
acquire the securities for investment only and not with a view
to or for sale in connection with any distribution thereof, and
appropriate legends were affixed to the stock certificates and
instruments issued in such transactions. All recipients received
adequate information regarding the Registrant and the stock sold.
Item 16. Exhibits and
Financial Statement Schedules
(a) Exhibits
|
|
|
|
|
Exhibit |
|
|
Number |
|
Description of Exhibit |
|
|
|
|
1 |
.1 |
|
Form of Underwriting Agreement between Catalyst Pharmaceutical
Partners, Inc. and the underwriters named therein(1) |
|
3 |
.1 |
|
Certificate of Incorporation(1) |
|
3 |
.2 |
|
Amendment to Certificate of Incorporation(1) |
|
3 |
.3 |
|
By-laws(1) |
|
4 |
.1 |
|
Specimen stock certificate for common stock(1) |
|
5 |
.1 |
|
Opinion of Akerman Senterfitt* |
|
10 |
.1 |
|
Form of Employment Agreement between the Company and Patrick J.
McEnany(1) |
|
10 |
.2 |
|
Form of Employment Agreement between the Company and Jack
Weinstein(1) |
|
10 |
.3 |
|
License Agreement, as amended, between the Company and
Brookhaven National Laboratories(1) |
|
10 |
.4 |
|
Stock Option Agreements between the Company and Patrick J.
McEnany(1) |
|
10 |
.5 |
|
Stock Option Agreements between the Company and Hubert Huckel(1) |
|
10 |
.6 |
|
Stock Option Agreements between the Company and Jack Weinstein(1) |
|
10 |
.7 |
|
Stock Option Agreement between the Company and Charles
OKeeffe(1) |
|
10 |
.8 |
|
2006 Stock Incentive Plan(1) |
|
10 |
.9 |
|
Agreement and Plan of Merger, dated August 14, 2006,
between the Company and Catalyst Pharmaceutical Partners, Inc.,
a Florida corporation(1) |
|
10 |
.10 |
|
Consulting Agreement, as amended, between the Company and Jack
Weinstein(1) |
|
10 |
.11 |
|
Consulting Agreement between the Company and Charles
OKeeffe(1) |
|
10 |
.12 |
|
Consulting Agreement between the Company and Donald R.
Jasinski(1) |
|
10 |
.13 |
|
Agreement between the Company and Charles Gorodetzky(1) |
|
10 |
.14 |
|
Agreement between the Company and Pharmaceutics International,
Inc.(1) |
|
23 |
.1 |
|
Consent of Grant Thornton LLP(1) |
|
23 |
.2 |
|
Consent of Akerman Senterfitt (included as Exhibit 5.1) |
|
24 |
.1 |
|
Power of Attorney (included on Page II-5) |
(1) Previously filed.
* Filed herewith.
II-3
(b) Financial Statement Schedules
None.
Item 17. Undertakings
(1) The undersigned registrant hereby undertakes to provide
to the underwriters at the closing specified in the Underwriting
Agreement certificates in such denominations and registered in
such names as required by the underwriters to permit prompt
delivery to each purchaser
(2) Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors,
officers, and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred
or paid by a director, officer, or a controlling person of the
registrant in the successful defense of any action, suit, or
proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in
the Act and will be governed by the final adjudication of such
issue.
(3) The undersigned registrant hereby undertakes that:
|
|
|
|
(a) |
For purposes of determining any liability under the Securities
Act of 1933, the information omitted from the form of the
prospectus filed as a part of this registration statement in
reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to
Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be a part of this registration statement
at the time it was declared effective. |
|
|
(b) |
For the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered
therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof. |
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as
amended, the registrant has duly caused this Amendment
No. 4 to Registration Statement on
Form S-1 to be
signed on its behalf by the undersigned, thereunto duly
authorized, in City of Miami, State of Florida on
October 18, 2006.
|
|
|
CATALYST PHARMACEUTICAL PARTNERS, INC. |
|
|
|
|
By: |
/s/ Patrick J. McEnany |
|
|
|
|
|
|
Patrick J. McEnany |
|
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this
Amendment No. 4 to Registration Statement on
Form S-1 has been
signed by the following persons, in the capacities and on the
dates indicated.
|
|
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
/s/ Patrick J. McEnany
Patrick
J. McEnany |
|
Chairman of the Board of Directors, President and Chief
Executive Officer (Principal Executive Officer) |
|
October 18, 2006 |
|
/s/ Jack Weinstein
Jack
Weinstein |
|
Vice President, Treasurer and
Chief Financial Officer (Principal Financial and Accounting
Officer) |
|
October 18, 2006 |
|
/s/ Hubert E. Huckel, M.D.*
Hubert
E. Huckel, M.D. |
|
Director |
|
October 18, 2006 |
|
/s/ Charles B. OKeeffe*
Charles
B. OKeeffe |
|
Director |
|
October 18, 2006 |
|
/s/ Philip H. Coelho*
Philip
H. Coelho |
|
Director |
|
October 18, 2006 |
|
/s/ David S. Tierney, M.D.*
David
S. Tierney, M.D. |
|
Director |
|
October 18, 2006 |
|
/s/ Milton J. Wallace*
Milton
J. Wallace |
|
Director |
|
October 18, 2006 |
|
*/s/ Patrick J. McEnany
By: Patrick
J. McEnany, under power of attorney dated July 25, 2006. |
|
|
|
|
II-5
EX-5.1 Opinion of Akerman Senterfitt
|
|
|
Fort Lauderdale
|
|
One Southeast Third Avenue |
Jacksonville
|
|
28th Floor |
Los Angeles
|
|
Miami, Florida 33131-1714 |
Madison |
|
|
Miami
|
|
www.akerman.com |
New York |
|
|
Orlando
|
|
305 374 5600 tel 305 374 5095 fax |
Tallahassee |
|
|
Tampa |
|
|
Tysons Corner |
|
|
Washington, DC |
|
|
West Palm Beach |
|
|
October 18, 2006
Catalyst Pharmaceutical Partners, Inc.
220 Miracle Mile
Suite 234
Coral Gables, FL 33134
Re: Registration Statement on Form S-1 (Registration No. 333-136039)
Ladies and Gentlemen:
We have acted as counsel to Catalyst Pharmaceutical Partners, Inc., a Delaware corporation
(the Company) in connection with the registration under the Securities Act of 1933, as amended
(the Act) of a public offering (the Offering) of up to 3,450,000 shares (the Shares) of the
Companys common stock, par value $0.001 per share, to be offered by the Company.
In our capacity as counsel, you have requested that we render the opinion set forth in this
letter and we are furnishing this opinion letter pursuant to Item 601(b)(5) of Regulation S-K
promulgated by the Securities and Exchange Commission (the Commission).
We have examined originals or copies, certified or otherwise identified to our satisfaction,
of (i) the Companys Registration Statement on Form S-1, Registration No. 333-136039 originally
filed with the Commission under the Act on July 25, 2006, as amended by Amendment No. 1, dated
September 1, 2006, Amendment No. 2 dated September 26, 2006, Amendment No. 3, dated October 4,
2006, and Amendment No. 4, dated as of this date (collectively, the Registration Statement); (ii)
the form of underwriting agreement, filed as Exhibit 1.1 to the Registration Statement (the
Underwriting Agreement) to be entered into by and among the Company and First Albany Capital and
Stifel Nicolaus, on their own behalf and on behalf of each of the other underwriters named in
Schedule 1 thereto, (iii) the Companys Certificate of Incorporation, as amended; (iv) the
Companys By-laws; (v) certain resolutions of
Catalyst Pharmaceutical Partners, Inc.
October 18, 2006
Page 2
_____________________________
the Board of Directors and the stockholders of the Company relating to the Offering, and (vi) such
other documents as we have deemed necessary or appropriate for purposes of rendering the opinion
set forth herein.
In our examination, we have assumed the legal capacity of all natural persons, the genuineness
of all signatures, the authenticity of all documents submitted to us as certified or photostatic
copies and the authenticity of the originals of such latter documents. As to any facts material to
the opinion expressed herein that were not independently established or verified, we have relied
upon statements and representations of officers and other representatives of the Company and
others. In addition, we have assumed the conformity of the certificates representing the Shares to
the form of the specimen thereof examined by us and the due execution and delivery of such
certificates.
The
law covered by this opinion letter is limited to Delaware General
Corporation Law, including the statutory provisions, all applicable
portions of the Delaware Constitution and reported judicial decisions
interpreting these laws.
Based upon and subject to the foregoing, we are of the opinion that when (i) the Board of
Directors of the Company or the pricing committee duly appointed by the Board of Directors
authorizes the price per Share, (ii) the duly appointed officers of the Company and the
underwriters execute and deliver the Underwriting Agreement and (iii) the Shares are issued and
delivered against payment therefor in accordance with the terms of the Underwriting Agreement, the
Shares will be duly authorized, validly issued, fully paid and non-assessable.
We hereby consent to the use of this opinion as an exhibit to the Registration Statement and
to the reference of this firm under the caption Legal Matters in the prospectus filed as a part
of the Registration Statement. In giving this consent, we do not admit that we are in the category
of persons whose consent is required under Section 7 of the Act or the rules and regulations of the
Commission thereunder.
As counsel to the Company, we have furnished this opinion letter to you in connection with the
filing of the Registration Statement. Except as otherwise set forth herein, this opinion letter may
not be used, circulated, quoted or otherwise referred to for any purpose or relied upon by any
other person without the express written consent of this firm.
Sincerely,
/s/ Akerman Senterfitt
AKERMAN SENTERFITT
Letter to the SEC
Catalyst Pharmaceutical Partners, Inc.
220 Miracle Mile
Suite 234
Coral Gables, Florida 33134
October 18, 2006
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E., Mail Stop 6010
Washington, DC 20549
Attn: Jeffrey Reidler, Assistant Director
|
|
|
Re:
|
|
Catalyst Pharmaceutical Partners, Inc.
Registration Statement on Form S-1
Commission File No. 333-136039 |
Dear Mr. Reidler:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the Act), Catalyst
Pharmaceutical Partners, Inc. (the Company) requests that the effectiveness of the
above-referenced Registration Statement be accelerated at 2:00 p.m. on Monday, October 23, 2006, or
as soon as possible thereafter.
As requested, the Company acknowledges that:
|
|
|
should the Commission or the staff declare the filing effective, it does not foreclose
the Commission from taking any action with respect to the filing; |
|
|
|
|
the action of the Commission or the staff, in declaring the filing effective, does not
relieve the Company from its full responsibility for the adequacy and accuracy of the
disclosures in the filing; and |
|
|
|
|
the company may not assert staff comments and the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States. |
Sincerely,
/s/ Patrick J. McEnany
Patrick J. McEnany
President and Chief Executive Officer
Catalyst Pharmaceutical Partners, Inc.